Gland Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported 72.30% fall in net profit at Rs 79.21 crore for the quarter under review as compared to Rs 285.98 crore for the same quarter in the previous year. Total income of the company decreased by 29.44% at Rs 824.36 crore for Q4FY23 as compared to Rs 1,168.25 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 72.48% fall in its net profit at Rs 78.68 crore for fourth quarter ended March 31, 2023 as compared to Rs 285.90 crore for the same quarter in the previous year. Total income of the company decreased by 29.47% at Rs 823.95 crore for Q4FY23 as compared to Rs 1,168.25 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 36% fall in its net profit at Rs 775.83 crore as compared to Rs 1,212.16 crore for the previous year. Total income of the company decreased by 16.60% at Rs 3,856.99 crore for year under review as compared to Rs 4,624.65 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 35.54% fall in its net profit at Rs 781.04 crore as compared to Rs 1,211.66 crore for the previous year. Total income of the company decreased by 16.42% at Rs 3,865.06 crore for year under review as compared to Rs 4,624.65 crore for year ended March 31, 2022.
